Relapsed Adult AMLPhase 2NCT07563010
Menin-Inhibitor Targeted Maintenance in AML
A Phase 2 study testing Revumenib in people with Relapsed Adult AML and Stem Cell Transplant Complications, run by Center for International Blood and Marrow Transplant Research.
Trial summary
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia
- What is being tested?
- Revumenib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 146 participants
- Where
- No sites listed yet
- Study dates
- Dec 2026to Jun 2031
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged ≥18 years at the time of signing informed consent
- Able to provide written informed consent personally or via a legally authorized representative in accordance with applicable regulatory and institutional requirements
- Willing and able to comply with all study procedures and available for the duration of the study
- Diagnosis of acute myeloid leukemia (AML) in complete morphologic remission with one of the following molecular abnormalities:
- 1. KMT2A-rearranged (KMT2Ar) AML (Excluding KMT2A partial tandem duplication (KMT2A-PTD) 2. NPM1-mutated (NPM1m) AML (Including FLT3-ITD or TKD co-mutation) 3. NUP98-rearranged (NUP98r) AML 5. Planned first allogeneic hematopoietic cell transplantation (allo-HCT) for AML.
- 6. Transplant Characteristics
Show all 20Show fewer
- Planned allo-HCT using bone marrow or peripheral blood stem cell graft source.
- Planned reduced-intensity/non-myeloablative conditioning (RIC/NMA) or myeloablative conditioning (MAC), using a conditioning regimen permitted- by the protocol and consistent with standard clinical practice, meeting CIBMTR criteria for conditioning intensity
- 7. Planned donor:
- HLA-matched related donor (5/6 or 6/6)
- Matched unrelated donor (8/8)
- Mismatched unrelated donor (7/8)
- Haploidentical donor meeting institutional requirements
- 8. Performance Status:
- 1. Karnofsky Performance Status ≥70%. 9. Cardiac Function: left ventricular ejection fraction (LVEF) by transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) with no clinical evidence of heart failure: RIC/NMA: ≥50% MAC: ≥5 10. Pulmonary function meeting the following criteria, without supplemental oxygen other than CPAP:
- RIC/NMA: DLCO (corrected for hemoglobin) and FEV1 ≥40% predicted
- MAC: DLCO and FEV1 ≥50% predicted
- 11. Renal Function: estimated creatinine clearance (CrCl) ≥45mL/min calculated using the Cockcroft-Gault formula or 24-hour urine collection, consistent with standard eligibility criteria for allogeneic HCT recipients.
- 12. Liver function acceptable per local institutional guidelines for allo-HCT eligibility.
- 13. Reproductive Status: Willingness to use contraception in accordance with local regulations from first study intervention through the required contraceptive period Willingness to use contraception in accordance with local regulations from first study intervention through the required contraceptive period
Who cannot join
- Disease Status:
- Evidence of active AML prior to HCT, assessed within 42 days before transplant, defined as any of the following:
- ≥5% bone marrow blasts
- Circulating blasts within 14 days before conditioning
- CNS or other extramedullary disease
- Other active malignancy that, in the investigator's judgment, could interfere with safety or efficacy assessment
Show all 30Show fewer
- Treatment with non-protocol antileukemic therapy (donor lymphocyte infusion for relapse prophylaxis or treatment will be considered an EFS event)
- Cardiac / QT Risk
- Requirement for concomitant medications known to prolong QT/QTc interval, except low-risk agents used as standard supportive care
- Diagnosis or suspicion of Long QT syndrome, or a family history of Long QT syndrome
- Fridericia's corrected QT interval (QTcF) >450 msec.
- History within 6 months of study entry of:
- Myocardial infarction ii. Unstable angina iii. Congestive heart failure (NYHA Class ≥ II) iv. Life-threatening or uncontrolled arrhythmia v. Cerebrovascular accident or transient ischemic attack
- Chronic respiratory disease requiring continuous supplemental oxygen, or other significant organ dysfunction that would adversely affect study participation.
- Active, uncontrolled infection, including any of the following:
- Active, uncontrolled systemic fungal, bacterial, or viral infection within 14 days prior to the start of conditioning
- Any other documented active, uncontrolled infection at the start of conditioning
- Chronic viral infections with evidence of active disease, including:
- HIV: detectable viral load within 6 months prior to screening
- Hepatitis B:
- HBsAg-positive and/or anti-HBc-positive with detectable HBV DNA
- Anti-HBc-positive alone Hepatitis C: positive HCV antibody with detectable HCV RNA
- Planned HCT using cord blood, ex vivo T cell depletion, engineered grafts, or experimental graft sources
- Malabsorption syndrome or GI condition that precludes oral administration, including:
- Inability to swallow oral medications
- Prior gastric bypass or severe gastroparesis
- Cirrhosis with Child-Pugh Class B or C
- Pregnant or breastfeeding
- Prior intolerance to menin inhibitor therapy resulting in ≥ Grade 3 treatment-related adverse events
- Any condition, therapy, laboratory abnormality, or allergy to excipients that, in the investigator's judgment, could confound study results, interfere with the participant's ability to comply with study procedures or complete the study, or make participation not in the participant's best interest.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With KMT2Ar, NPM1m, or NUP98r Acute Myeloid Leukemia (AML)
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.
Read the detailed description
Menin is a critical cofactor for oncogenic transcriptional programs in AML subsets driven by KMT2A rearrangements, NPM1 mutations, and NUP98 rearrangements. The interaction between menin and KMT2A promotes aberrant expression of HOX and MEIS genes, maintaining leukemic self-renewal and blocking differentiation. Revumenib is a potent, selective, oral small-molecule inhibitor of the menin-KMT2A interaction that has demonstrated clinical activity in relapsed or refractory AML. Beyond its direct anti-leukemic effects, emerging preclinical data indicate that menin inhibition may favorably modulate leukemia-immune interactions in the post-transplant environment. Menin inhibition has been shown to induce myeloid differentiation and increase expression of antigen presentation machinery, including MHC class II, in KMT2Ar and NPM1m AML. This effect is mediated through activation of interferon-related signaling pathways and results in enhanced recognition of leukemia cells by donor T cells. In parallel, menin inhibition has been shown to augment donor T-cell effector function and reduce T-cell exhaustion, collectively strengthening the GVL response without directly increasing alloreactivity against normal tissues.
- Conditions
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
- Being tested
- Revumenib, Placebo
- Keywords
- Allogenic Transplant, post-transplant relapse prevention
- Medical subject headings
- Leukemia, Myeloid, Acute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RevumenibDrug
Also called Revuforj
oral tablets
PlaceboDrug
oral tablets
| Study group | Role | What they receive |
|---|---|---|
| Revumenib BID | Experimental | For patients not taking strong CYP3A4 inhibitor and patients taking strong CYP3A4 inhibitor Receives: Drug: Revumenib |
| Placebo BID | Placebo comparator | For patients not taking strong CYP3A4 inhibitor and patients taking strong CYP3A4 inhibitor Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Relapse free survival (RFS) in KMT2Ar, NPM1m, and NUP98r AML in the Intent-to-Treat (ITT) population with a minimum of 1 year of follow-up post-randomization.
RFS is defined as the time from randomization to the date of relapse or the date of death from any cause, whichever comes first.
Measured: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization.
Secondary outcomes (9)
RFS in the modified ITT (mITT) population
Relapse free survival rate in modified intent to treat population
Measured: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization
Rate of overall survival (OS) in the ITT population
Overall survival rate in the intent-to-treat population
Measured: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization.
Incidence of relapse in the ITT population
Incidence of relapses in intent-to-treat participant population
Measured: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization.
Rate of event-free survival (EFS) in the ITT population
Events such as relapse/progression, death from any cause, graft failure, use of donor lymphocyte infusion which have occurred from time from the date of randomization to the date of event occurrence.
Measured: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization
Rate of non-relapse mortality (NRM) in the ITT population
Death in participants in the absence of disease progression or relapse
Measured: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization.
Frequency, duration, and severity of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (TRAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) in the Safety Analysis population
Documentation of number of treatment related of adverse events; their frequencies, duration, and severity
Measured: From date of randomization to end of treatment, assessed for a minimum of 1 year post-randomization
Change from baseline in other observations related to safety for electrocardiograms (ECGs) measuring QT intervals.
Documentation and comparison of abnormal ECGs from baseline measurements in relationship to safety
Measured: From date of randomization to end of treatment, assessed for a minimum of 1 year post-randomization.
Change from baseline in other observations related to safety for vital signs.
Documentation and comparison of abnormal vital signs from baseline measurements in relationship to safety
Measured: From date of randomization to end of treatment, assessed for a minimum of 1 year post-randomization.
Change from baseline in other observations related to safety for performance status in the Safety Analysis population
Documentation and comparison of abnormal performance from baseline measurements in relationship to safety
Measured: From date of randomization to end of treatment, assessed for a minimum of 1 year post-randomization.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2026
- Study startDec 2026 (estimated)
- Primary completionJun 2031 (estimated)
- Study completionJun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Relapsed Adult AMLStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 146 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Sponsor type
- Research network
- Collaborators
- National Marrow Donor Program, Dana-Farber Cancer Institute
- Responsible party
- Sponsor
- Investigators
- Steven Devine, M.D, Study chair, NMDP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07563010
- Sponsor's protocol ID
- MENTAIN
- Status last verified
- Jun 2026
- First submitted
- 15 Apr 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No